SCHEMBL16394635

SCHEMBL16394635

CC1(C)C(=O)Nc2cc(Nc3nc4c(N5CCc6ccc(C#N)cc6C5)nccn4n3)ccc21

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.43
▸ EIF2AK4 Q9P2K8 1/20 0.43
▸ JAK2 O60674 11/20 0.35
▸ TBK1 Q9UHD2 2/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ JAK1 P23458 6/20 0.35
▸ GRIA1 P42261 1/20 0.35
▸ MAP3K14 Q99558 1/20 0.34
▸ PTK2 Q05397 4/20 0.34
▸ JAK3 P52333 3/20 0.34
▸ TNK2 Q07912 1/20 0.33
▸ TNF P01375 1/20 0.33
▸ LCK P06239 1/20 0.33
▸ BRAF P15056 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ MAPK14 Q16539 1/20 0.33
▸ WEE1 P30291 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210643 0.88 SYK (0.43) SYKEIF2AK4JAK2TBK1JAK1
SCHEMBL16394520 0.87 SYK (0.44) SYKEIF2AK4JAK2TBK1JAK1
SCHEMBL15210928 0.86 SYK (0.44) SYKEIF2AK4JAK2TBK1JAK1
SCHEMBL16407147 0.83 SYK (0.46) SYKEIF2AK4JAK2ROCK2JAK1
SCHEMBL15210652 0.83 SYK (0.45) SYKEIF2AK4LCKBRAFKDR
SCHEMBL15210624 0.83 SYK (0.47) SYKEIF2AK4JAK2JAK1GRIA1
SCHEMBL15210740 0.82 SYK (0.51) SYKEIF2AK4JAK2TBK1JAK1
SCHEMBL15210712 0.82 SYK (0.45) SYKEIF2AK4JAK2TBK1JAK1
SCHEMBL16394673 0.81 SYK (0.50) SYKEIF2AK4JAK2TBK1JAK1
SCHEMBL15212586 0.81 SYK (0.50) SYKEIF2AK4JAK2TBK1JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 — — US claimed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 — — EP disclosed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 — — EP disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 — — US disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 — — US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 — — US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS SYK, EIF2AK4, BTK SYK 1/4885EIF2AK4 2/4885JAK2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback